(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Enlivex Therapeutics's earnings in 2026 is -$12,701,000.On average, 4 Wall Street analysts forecast ENLV's earnings for 2026 to be -$7,929,181, with the lowest ENLV earnings forecast at -$14,046,116, and the highest ENLV earnings forecast at -$1,275,374. On average, 3 Wall Street analysts forecast ENLV's earnings for 2027 to be -$19,327,378, with the lowest ENLV earnings forecast at -$18,569,442, and the highest ENLV earnings forecast at -$19,895,830.
In 2028, ENLV is forecast to generate -$23,291,968 in earnings, with the lowest earnings forecast at -$22,378,558 and the highest earnings forecast at -$23,977,026.